Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.40 |
| ▸ | PARP1 | P09874 | 4/20 | 0.40 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.39 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.39 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.39 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22559041 | 0.85 | CYP1A2 (0.39) | PARP1CYP1A2CYP3A4TSHRLMNA | |
| SCHEMBL14477036 | 0.82 | TSHR (0.42) | TAAR1PARP1TSHRSMN1; SMN2PDPK1 | |
| SCHEMBL2496016 | 0.81 | PARP1 (0.35) | PARP1SMN1; SMN2PDPK1CA12ALOX15 | |
| SCHEMBL2497541 | 0.81 | CXCL8 (0.39) | PARP1CYP1A2CYP3A4LMNAHPGD | |
| SCHEMBL3866726 | 0.80 | PARP1 (0.37) | TAAR1PARP1TSHRSMN1; SMN2PDPK1 | |
| SCHEMBL2820813 | 0.80 | CXCL8 (0.40) | PARP1CYP1A2SMN1; SMN2PDPK1CA12 | |
| SCHEMBL16746098 | 0.76 | KDM5B (0.33) | PARP1HSP90AB1 | |
| SCHEMBL11379842 | 0.75 | PARP1 (0.63) | TAAR1PARP1SMN1; SMN2PDPK1CA12 | |
| SCHEMBL20889995 | 0.74 | CSNK2A1 (0.34) | PARP1PAK1HSP90AB1 | |
| SCHEMBL8668 | 0.74 | PARP1 (0.56) | TAAR1PARP1HPGDSMN1; SMN2PDPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240174583-A1 | PROCESSES FOR THE VAPOR PHASE HYDROGENATION OF ALDEHYDES | DOW TECHNOLOGY INVESTMENTS LLC (US) | 2024-05-30 | — | — | US | disclosed |
| WO-2024108155-A2 | COMPOUNDS, COMPOSITIONS, AND METHODS | DENALI THERAPEUTICS INC. (US) | 2024-05-23 | — | — | WO | disclosed |
| EP-4347544-A1 | PROCESSES FOR THE VAPOR PHASE HYDROGENATION OF ALDEHYDES | Dow Technology Investments LLC (US) | 2024-04-10 | — | — | EP | disclosed |
| US-20240025918-A1 | KRAS G12D Inhibitors | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2024-01-25 | — | — | US | disclosed |
| US-20230322747-A1 | OXADIAZOLE HDAC6 INHIBITORS AND USES THEREOF | EIKONIZO THERAPEUTICS, INC. (US) | 2023-10-12 | — | — | US | disclosed |
| WO-2023196601-A1 | OXADIAZOLE HDAC6 INHIBITORS AND USES THEREOF | EIKONIZO THERAPEUTICS, INC. (US) | 2023-10-12 | — | — | WO | disclosed |
| WO-2023196283-A1 | EGFR INHIBITORS | BLUEPRINT MEDICINES CORPORATION (US) | 2023-10-12 | — | — | WO | disclosed |
| US-20230242531-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-08-03 | — | — | US | disclosed |
| US-20230203060-A1 | FUSED TRICYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | GENFLEET THERAPEUTICS (SHANGHAI) INC. (CN) | 2023-06-29 | — | — | US | disclosed |
| WO-2023098815-A1 | AROMATIC COMPOUND, PHARMACEUTICAL COMPOSITION, AND APPLICATION THEREOF | 上海栖臻医药科技有限公司 | 2023-06-08 | — | — | WO | disclosed |
| US-20120015931-A1 | PURINE COMPOUNDS SELECTIVE FOR PI3K P110 DELTA, AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2012-01-19 | — | — | US | disclosed |
| US-20110118285-A1 | HETEROCYCLES AS PROTEIN KINASE INHIBITORS | AMGEN INC. | 2011-05-19 | — | — | US | disclosed |
| US-20090318436-A1 | Fused heterocyclic derivatives and methods of use | AMGEN INC. (US) | 2009-12-24 | — | — | US | disclosed |
| US-6875765-B2 | Arylsulfonamide ethers, and methods of use thereof | WARNER-LAMBERT COMPANY (US) | 2005-04-05 | — | — | US | disclosed |
| US-6875765-B2 | Arylsulfonamide ethers, and methods of use thereof | WARNER-LAMBERT COMPANY (US) | 2005-04-05 | — | — | US | disclosed |
| EP-0873292-B1 | IMPROVED METAL-LIGAND COMPLEX CATALYZED PROCESSES | UNION CARBIDE CHEM PLASTIC (US) | 2001-12-19 | — | — | EP | disclosed |
| EP-0873292-A1 | IMPROVED METAL-LIGAND COMPLEX CATALYZED PROCESSES | UNION CARBIDE CHEMICALS & PLASTICS TECHNOLOGY CORPORATION (US) | 1998-10-28 | — | — | EP | disclosed |
| US-5731472-A | HETEROCYCLIC NITROGEN COMPOUNDS | UNION CARBIDE CHEMICALS & PLASTICS TECHNOLOGY CORPORATION (US) | 1998-03-24 | — | — | US | disclosed |
| WO-1997020798-A1 | IMPROVED METAL-LIGAND COMPLEX CATALYZED PROCESSES | UNION CARBIDE CHEMICALS & PLASTICS TECHNOLOGY CORPORATION (US) | 1997-06-12 | — | — | WO | disclosed |
| US-3985563-A | Silver halide photographic emulsion | FUJI PHOTO FILM CO., LTD. (JA) | 1976-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322747-A1 | OXADIAZOLE HDAC6 INHIBITORS AND USES THEREOF | HDAC6, HDAC1, HDAC11 | TAAR1 4007/4885PARP1 1626/4885GABRA1 2677/4885 |
| US-20090318436-A1 | Fused heterocyclic derivatives and methods of use | HGF, HGFAC, MET | TAAR1 4599/4885PARP1 1457/4885GABRA1 2292/4885 |
| US-20230242531-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | TAAR1 828/4885PARP1 2550/4885GABRA1 859/4885 |
| US-20230203060-A1 | FUSED TRICYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | KRAS, NRAS, TP53 | TAAR1 4690/4885PARP1 1011/4885GABRA1 3287/4885 |
| US-20110118285-A1 | HETEROCYCLES AS PROTEIN KINASE INHIBITORS | HGF, HGFAC, MET | TAAR1 4086/4885PARP1 1374/4885GABRA1 2537/4885 |
| US-20120015931-A1 | PURINE COMPOUNDS SELECTIVE FOR PI3K P110 DELTA, AND METHODS OF USE | PIK3CA, PIK3CD, PIK3CG | TAAR1 1686/4885PARP1 564/4885GABRA1 2678/4885 |
| US-20240174583-A1 | PROCESSES FOR THE VAPOR PHASE HYDROGENATION OF ALDEHYDES | ADH1C, ADH5, ALDH2 | TAAR1 339/4885PARP1 2414/4885GABRA1 2824/4885 |
| US-20240025918-A1 | KRAS G12D Inhibitors | KRAS, NRAS, HRAS | TAAR1 4793/4885PARP1 1024/4885GABRA1 3975/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.